Targeting the aldosterone pathway in cardiovascular disease

Fundamental and Clinical Pharmacology

Volumn 26, Issue 1, 2012, Pages 135-145

  Gustafsson, Finn ^a   Azizi, Michel ^b,c,d   Bauersachs, Johann ^e   Jaisser, Frederic ^f   Rossignol, Patrick ^d,g  

^a Rigshospitalet   (Denmark)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSERM   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Eplerenone; Heart failure; Hypertension; Mineralocorticoid; Spironolactone

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; CANRENONE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; EPLERENONE; FADROZOLE; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; PLACEBO; PRASTERONE; SPIRONOLACTONE;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ADIPOSE TISSUE; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DRUG TARGETING; ENDOTHELIAL PROGENITOR CELL; GENE EXPRESSION; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN SENSITIVITY; MOLECULAR PATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REVIEW; SALT INTAKE;

ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GLUCOCORTICOIDS; HUMANS; RECEPTORS, MINERALOCORTICOID; TREATMENT OUTCOME;

EID: 84855684305     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.01004.x     Document Type: Review

References (92)

1. Doi M., Takahashi Y., Komatsu R. et al. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat. Med. (2010) 16 67-74.
2. Michea L., Delpiano A.M., Hitschfeld C., Lobos L., Lavandero S., Marusic E.T. Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology (2005) 146 973-980.
3. Uhrenholt T.R., Schjerning J., Hansen P.B. et al. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ. Res. (2003) 93 1258-1266.
4. Funder J., Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology (1996) 137 5264-5268.
5. Edwards C.R., Stewart P.M., Burt D. et al. Localisation of 11 beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet (1988) 2 986-989.
6. Sheppard K.E., Autelitano D.J. 11Beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology (2002) 143 198-204.
7. Qin W., Rudolph A.E., Bond B.R. et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ. Res. (2003) 93 69-76.
8. Mihailidou A.S., Loan Le T.Y., Mardini M., Funder J.W. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension (2009) 54 1306-1312.
9. Klusonova P., Rehakova L., Borchert G. et al. Chronic intermittent hypoxia induces 11beta-hydroxysteroid dehydrogenase in rat heart. Endocrinology (2009) 150 4270-4277.
10. Lacolley P., Safar M.E., Lucet B., Ledudal K., Labat C., Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J. Am. Coll. Cardiol. (2001) 37 662-667.
11. Benetos A., Gardner J.P., Kimura M. et al. Aldosterone and telomere length in white blood cells. J. Gerontol. A Biol. Sci. Med. Sci. (2005) 60 1593-1596.
12. Henschkowski J., Stuck A.E., Frey B.M. et al. Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients. Am. J. Hypertens. (2008) 21 644-649.
13. Chang L.L., Wun W.S., Wang P.S. Effects of dehydroepiandrosterone on aldosterone release in rat zona glomerulosa cells. J. Biomed. Sci. (2008) 15 463-470.
14. Rossi G.P., Bernini G., Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1, 125 hypertensive patients. J. Am. Coll. Cardiol. (2006) 48 2293-2300.
15. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. (2005) 45 1243-1248.
16. Vasan R.S., Evans J.C., Larson M.G. et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. (2004) 351 33-41.
17. Meneton P., Galan P., Bertrais S., Heudes D., Hercberg S., Menard J. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations. J. Hum. Hypertens. (2008) 22 550-558.
18. Tomaschitz A., Maerz W., Pilz S. et al. Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J. Am. Coll. Cardiol. (2010) 55 2171-2180.
19. Imanishi T., Ikejima H., Tsujioka H. et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension (2008) 51 734-741.
20. Mazak I., Fiebeler A., Muller D.N. et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation (2004) 109 2792-2800.
21. Nguyen Dinh Cat A., Griol-Charhbili V., Loufrani L. et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. (2010) 24 2454-2463.
22. Rickard A.J., Morgan J., Tesch G., Funder J.W., Fuller P.J., Young M.J. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension (2009) 54 537-543.
23. de Souza F., Muxfeldt E., Fiszman R., Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension (2010) 55 147-152.
24. Pitt B., Reichek N., Willenbrock R. et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation (2003) 108 1831-1838.
25. Vukusich A., Kunstmann S., Varela C. et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin. J. Am. Soc. Nephrol. (2010) 5 1380-1387.
26. Kawarazaki H., Ando K., Fujita M. et al. Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats. Am. J. Physiol. Renal. Physiol. (2011) 300 F1402-F1409.
27. Nowaczynski W., Oliver W.J., Neel J.V. Serum aldosterone and protein-binding variables in Yanomama Indians: a no-salt culture as compared to partially acculturated Guaymi Indians. Clin. Physiol. Biochem. (1985) 3 289-306.
28. Hirata A., Maeda N., Hiuge A. et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc. Res. (2009) 84 164-172.
29. Wada T., Kenmochi H., Miyashita Y. et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology (2010) 151 2040-2049.
30. Swaminathan K., Davies J., George J., Rajendra N.S., Morris A.D., Struthers A.D. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia (2008) 51 762-768.
31. Davies J.I., Band M., Morris A., Struthers A.D. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia (2004) 47 1687-1694.
32. Schjoedt K.J., Rossing K., Juhl T.R. et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. (2005) 68 2829-2836.
33. Matrozova J., Steichen O., Amar L., Zacharieva S., Jeunemaitre X., Plouin P.F. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension (2009) 53 605-610.
34. Schafer A., Vogt C., Fraccarollo D. et al. Eplerenone improves vascular function and reduces platelet activation in diabetic rats. J. Physiol. Pharmacol. (2010) 61 45-52.
35. Epstein M., Williams G.H., Weinberger M. et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. (2006) 1 940-951.
36. Beygui F., Collet J.P., Benoliel J.J. et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation (2006) 114 2604-2610.
37. Palmer B.R., Pilbrow A.P., Frampton C.M. et al. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur. Heart J. (2008) 29 2489-2496.
38. Tomaschitz A., Pilz S., Ritz E., Meinitzer A., Boehm B.O., Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur. Heart J. (2010) 31 1237-1247.
39. de Resende M.M., Kauser K., Mill J.G. Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats. Life Sci. (2006) 78 3066-3073.
40. Takeda M., Tatsumi T., Matsunaga S. et al. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens. Res. (2007) 30 427-437.
41. Fraccarollo D., Galuppo P., Hildemann S., Christ M., Ertl G., Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J. Am. Coll. Cardiol. (2003) 42 1666-1673.
42. Fraccarollo D., Galuppo P., Schmidt I., Ertl G., Bauersachs J. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Cardiovasc. Res. (2005) 67 97-105.
43. Schmidt K., Tissier R., Ghaleh B., Drogies T., Felix S.B., Krieg T. Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion. Eur. Heart J. (2010) 31 1655-1662.
44. Kayrak M., Bacaksiz A., Vatankulu M.A. et al. The effects of spironolactone on atrial remodeling in patients with preserved left ventricular function after an acute myocardial infarction: a randomized follow-up study. Coron. Artery Dis. (2010) 21 477-485.
45. Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348 1309-1321.
46. Pitt B., White H., Nicolau J. et al. Eplerenone reduces mortality 30days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J. Am. Coll. Cardiol. (2005) 46 425-431.
47. Adamopoulos C., Ahmed A., Fay R. et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur. J. Heart Fail. (2009) 11 1099-1105.
48. Hayashi M., Tsutamoto T., Wada A. et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation (2003) 107 2559-2565.
49. Fraccarollo D., Galuppo P., Schraut S. et al. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension (2008) 51 905-914.
50. Fraccarollo D., Berger S., Galuppo P. et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation (2011) 123 400-408.
51. Thum T., Schmitter K., Fleissner F. et al. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur. Heart J. (2010) 32 1275-1286.
52. Perrier E., Kerfant B.G., Lalevee N. et al. Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation (2004) 110 776-783.
53. Gomez A.M., Rueda A., Sainte-Marie Y. et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation (2009) 119 2179-2187.
54. Ouvrard-Pascaud A., Sainte-Marie Y., Benitah J.P. et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation (2005) 111 3025-3033.
55. Pitt B., Bakris G., Ruilope L.M., DiCarlo L., Mukherjee R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation (2008) 118 1643-1650.
56. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation (1990) 82 1730-1736.
57. Vantrimpont P., Rouleau J.L., Ciampi A. et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur. Heart J. (1998) 19 1552-1563.
58. Guder G., Bauersachs J., Frantz S. et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation (2007) 115 1754-1761.
59. Dickstein K., Cohen-Solal A., Filippatos G. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. (2008) 29 2388-2442.
60. Hunt S.A., Abraham W.T., Chin M.H. et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation (2005) 112 e154-e235.
61. Udelson J.E., Feldman A.M., Greenberg B. et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ. Heart Fail. (2010) 3 347-353.
62. Zannad F., McMurray J.J., Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. (2011) 364 11-21.
63. Ezekowitz J.A., McAlister F.A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur. Heart J. (2009) 30 469-477.
64. Chan A.K., Sanderson J.E., Wang T. et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J. Am. Coll. Cardiol. (2007) 50 591-596.
65. Mottram P.M., Haluska B., Leano R., Cowley D., Stowasser M., Marwick T.H. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation (2004) 110 558-565.
66. Tsukamoto O., Minamino T., Sanada S. et al. The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. Cardiovasc. Drugs Ther. (2006) 20 93-102.
67. Cittadini A., Monti M.G., Isgaard J. et al. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc. Res. (2003) 58 555-564.
68. Mohammed S.F., Ohtani T., Korinek J. et al. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". Circulation (2010) 122 370-378.
69. Hillege H.L., Nitsch D., Pfeffer M.A. et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 113 671-678.
70. Kambara A., Holycross B.J., Wung P. et al. Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. J. Cardiovasc. Pharmacol. (2003) 41 830-837.
71. Juurlink D.N., Mamdani M.M., Lee D.S. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. (2004) 351 543-551.
72. Svensson M., Gustafsson F., Galatius S., Hildebrandt P., Atar D. Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ (2003) 327 1141-1142.
73. Bozkurt B., Agoston I., Knowlton A.A. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J. Am. Coll. Cardiol. (2003) 41 211-214.
74. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. (1999) 341 709-717.
75. Wei L., Struthers A.D., Fahey T., Watson A.D., Macdonald T.M. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ (2010) 340 c1768.
76. Rossignol P., Menard J., Fay R., Gustafsson F., Pitt B., Zannad F. Eplerenone Survival Benefits in Heart Failure Patients Post Myocardial Infarction are Independent from its Diuretic and Potassium-sparing effects. Insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy. J. Am. Coll. Cardiol. (2011) in press.
77. Matsumoto Y., Kageyama S., Yakushigawa T. et al. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology (2009) 114 32-38.
78. Pitt B., Anker S.D., Bushinsky D.A., Kitzman D.W., Zannad F., Huang I.Z. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur. Heart J. (2011) 32 820-828.
79. Parthasarathy H.K., Menard J., White W.B. et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J. Hypertens. (2011) 29 980-990.
80. Karagiannis A., Tziomalos K., Papageorgiou A. et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin. Pharmacother. (2008) 9 509-515.
81. Yamaji M., Tsutamoto T., Kawahara C. et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure. Am. Heart J. (2010) 160 915-921.
82. Karagiannis A., Tziomalos K., Kakafika A., Florentin M., Athyros V.G. Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. Nephrol. Dial. Transplant. (2007) 22 293.
83. Boccanelli A., Mureddu G.F., Cacciatore G. et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur. J. Heart Fail. (2009) 11 68-76.
84. Menard J., Gonzalez M.F., Guyene T.T., Bissery A. Investigation of aldosterone-synthase inhibition in rats. J. Hypertens. (2006) 24 1147-1155.
85. Trunet P.F., Mueller P., Girard F. et al. The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. J. Clin. Endocrinol. Metab. (1992) 74 571-576.
86. Fiebeler A., Nussberger J., Shagdarsuren E. et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation (2005) 111 3087-3094.
87. Lea W.B., Kwak E.S., Luther J.M. et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. (2009) 75 936-944.
88. Amar L., Azizi M., Menard J., Peyrard S., Watson C., Plouin P.F. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension (2010) 56 831-838.
89. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342 145-153.
90. Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. (2008) 358 1547-1559.
91. Beygui F., Vicaut E., Ecollan P. et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am. Heart J. (2010) 160 642-648.
92. Edelmann F., Schmidt A.G., Gelbrich G. et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur. J. Heart Fail. (2010) 12 874-882.